Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00334282 · OUTCOME

Overall Survival

Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma · Source last updated 2016-02-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Randomization until death (up to 2 years)

What was measured

Overall survival is defined as the time from randomization until death. The length of this interval was estimated as the date of death minus the date of randomization plus 1 day. Participants who were still alive at the time of analysis were censored.

Analysis population: ITT Population

Groups in this outcome

Pazopanib 800 mg

Pazopanib 800 mg (tablets) administered orally once a day

Placebo

Matching Placebo administered orally once a day

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg290
Placebo145

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg22.9Not reported19.925.4Not reported
Placebo20.5Not reported15.627.6Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        19.9
        upper Limit
        25.4
        value
        22.9
      2. group Id
        OG001
        lower Limit
        15.6
        upper Limit
        27.6
        value
        20.5
denoms
  1. counts
    1. group Id
      OG000
      value
      290
    2. group Id
      OG001
      value
      145
    units
    Participants
description
Overall survival is defined as the time from randomization until death. The length of this interval was estimated as the date of death minus the date of randomization plus 1 day. Participants who were still alive at the time of analysis were censored.
dispersion Type
95% Confidence Interval
groups
  1. description
    Pazopanib 800 mg (tablets) administered orally once a day
    id
    OG000
    title
    Pazopanib 800 mg
  2. description
    Matching Placebo administered orally once a day
    id
    OG001
    title
    Placebo
param Type
MEDIAN
population Description
ITT Population
reporting Status
POSTED
time Frame
Randomization until death (up to 2 years)
title
Overall Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice